NSW Cancer Research Education

Statewide Seminar Series 2024 Tuesday 16 April 12.30 - 1.30 pm

Liquid Biopsy in Cancer



Professor Helen RizosProfessor, Cancer Research, Macquarie Medical School,
Macquarie University

Dr Kristina Warton Senior Research Fellow, School of Clinical Medicine, UNSW Sydney



Chair: Professor Caroline Ford, Professor, School of Clinical Medicine, UNSW Sydney





REGISTER NOW

Supported by the Cancer Institute NSW Translation Cancer Research Capacity Building Grants







Session Information

Liquid biopsies of blood, urine, or other body fluid such as ascites are gaining interest in cancer diagnostics and treatment. Liquid biopsies are used to identify presence of cancer cells or small fragmented pieces of DNA, RNA, or other molecules released by cancer cells into body fluids. Liquid biopsies may be used to detect cancer at an early stage and hold great promise for population screening for early cancer detection.

Liquid biopsy allows multiple samples to be taken over time, which may help to understand genetic or molecular changes as they are taking place to improve treatment approaches and outcomes for patients. It may also be used to determine how well treatment is working and to detect recurrence earlier.

In this session Professor Helen Rizos will discuss liquid biopsies in melanoma – how they can monitor response, predict patient outcomes and current limitations in the application of liquid biopsies and Dr Kristina Warton will present on using liquid biopsies for early detection of gynaecological cancers.

Speakers



Professor Helen Rizos leads the Precision Cancer Therapy research team and is Principle Investigator of the Macquarie University Cancer Biobank in the Macquarie School of Medicine, Faculty of Medicine, Health and Human Sciences at Macquarie University. She is a Faculty member of the Melanoma Institute Australia, where she co-leads the Advanced Melanoma research theme.

She joined Macquarie University in 2013, and was Head, Department of Biomedical Sciences, Faculty of Medicine, Health and Human Sciences from 2014-2021.

Dr Kristina Warton completed her PhD at the University of New South Wales, before working for a number of years in biotech and then returning to academia. She is currently leading a project within the Gynaecological Cancer Research Group to develop a blood test for the early diagnosis of ovarian cancer.







